カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界の肺塞栓症治療薬市場予測2023-2029：DS-9231、DS-1040、TRX-1、その他

【英語タイトル】Pulmonary Embolism Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23LY8619）・商品コード：MMG23LY8619
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年7月
・ページ数：74
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の肺塞栓症治療薬市場規模と予測を収録しています。・世界の肺塞栓症治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の肺塞栓症治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の肺塞栓症治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「DS-9231」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

肺塞栓症治療薬のグローバル主要企業は、Accu-Break Pharmaceuticals, Inc.、 Dong-A Socio Holdings Co. Ltd.、 F. Hoffmann-La Roche Ltd.、 Genentech, Inc.、 Verseon Corpなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、肺塞栓症治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の肺塞栓症治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の肺塞栓症治療薬市場：タイプ別市場シェア、2022年
・DS-9231、DS-1040、TRX-1、その他

世界の肺塞栓症治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の肺塞栓症治療薬市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の肺塞栓症治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の肺塞栓症治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における肺塞栓症治療薬のグローバル売上、2018年-2023年
・主要企業における肺塞栓症治療薬のグローバル売上シェア、2022年
・主要企業における肺塞栓症治療薬のグローバル販売量、2018年-2023年
・主要企業における肺塞栓症治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Accu-Break Pharmaceuticals, Inc.、 Dong-A Socio Holdings Co. Ltd.、 F. Hoffmann-La Roche Ltd.、 Genentech, Inc.、 Verseon Corp

*************************************************************

・調査・分析レポートの概要
肺塞栓症治療薬市場の定義
市場セグメント
世界の肺塞栓症治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の肺塞栓症治療薬市場規模
世界の肺塞栓症治療薬市場規模：2022年 VS 2029年
世界の肺塞栓症治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの肺塞栓症治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の肺塞栓症治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：DS-9231、DS-1040、TRX-1、その他
肺塞栓症治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
肺塞栓症治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別肺塞栓症治療薬市場規模 2022年と2029年
地域別肺塞栓症治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Accu-Break Pharmaceuticals, Inc.、 Dong-A Socio Holdings Co. Ltd.、 F. Hoffmann-La Roche Ltd.、 Genentech, Inc.、 Verseon Corp
...

This report aims to provide a comprehensive presentation of the global market for Pulmonary Embolism Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Embolism Drug. This report contains market size and forecasts of Pulmonary Embolism Drug in global, including the following market information:
Global Pulmonary Embolism Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Pulmonary Embolism Drug Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Pulmonary Embolism Drug companies in 2022 (%)
The global Pulmonary Embolism Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
DS-9231 Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Embolism Drug include Accu-Break Pharmaceuticals, Inc., Dong-A Socio Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech, Inc. and Verseon Corp, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pulmonary Embolism Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Embolism Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pulmonary Embolism Drug Market Segment Percentages, by Type, 2022 (%)
DS-9231
DS-1040
TRX-1
Others
Global Pulmonary Embolism Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pulmonary Embolism Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Pulmonary Embolism Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pulmonary Embolism Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Embolism Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Pulmonary Embolism Drug revenues share in global market, 2022 (%)
Key companies Pulmonary Embolism Drug sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Pulmonary Embolism Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Accu-Break Pharmaceuticals, Inc.
Dong-A Socio Holdings Co. Ltd.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Verseon Corp
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pulmonary Embolism Drug, market overview.
Chapter 2: Global Pulmonary Embolism Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Pulmonary Embolism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pulmonary Embolism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Pulmonary Embolism Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Pulmonary Embolism Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pulmonary Embolism Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pulmonary Embolism Drug Overall Market Size
2.1 Global Pulmonary Embolism Drug Market Size: 2022 VS 2029
2.2 Global Pulmonary Embolism Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Pulmonary Embolism Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Pulmonary Embolism Drug Players in Global Market
3.2 Top Global Pulmonary Embolism Drug Companies Ranked by Revenue
3.3 Global Pulmonary Embolism Drug Revenue by Companies
3.4 Global Pulmonary Embolism Drug Sales by Companies
3.5 Global Pulmonary Embolism Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Pulmonary Embolism Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Pulmonary Embolism Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Pulmonary Embolism Drug Players in Global Market
3.8.1 List of Global Tier 1 Pulmonary Embolism Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Pulmonary Embolism Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Pulmonary Embolism Drug Market Size Markets, 2022 & 2029
4.1.2 DS-9231
4.1.3 DS-1040
4.1.4 TRX-1
4.1.5 Others
4.2 By Type – Global Pulmonary Embolism Drug Revenue & Forecasts
4.2.1 By Type – Global Pulmonary Embolism Drug Revenue, 2018-2023
4.2.2 By Type – Global Pulmonary Embolism Drug Revenue, 2024-2029
4.2.3 By Type – Global Pulmonary Embolism Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Pulmonary Embolism Drug Sales & Forecasts
4.3.1 By Type – Global Pulmonary Embolism Drug Sales, 2018-2023
4.3.2 By Type – Global Pulmonary Embolism Drug Sales, 2024-2029
4.3.3 By Type – Global Pulmonary Embolism Drug Sales Market Share, 2018-2029
4.4 By Type – Global Pulmonary Embolism Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Pulmonary Embolism Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Pulmonary Embolism Drug Revenue & Forecasts
5.2.1 By Application – Global Pulmonary Embolism Drug Revenue, 2018-2023
5.2.2 By Application – Global Pulmonary Embolism Drug Revenue, 2024-2029
5.2.3 By Application – Global Pulmonary Embolism Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Pulmonary Embolism Drug Sales & Forecasts
5.3.1 By Application – Global Pulmonary Embolism Drug Sales, 2018-2023
5.3.2 By Application – Global Pulmonary Embolism Drug Sales, 2024-2029
5.3.3 By Application – Global Pulmonary Embolism Drug Sales Market Share, 2018-2029
5.4 By Application – Global Pulmonary Embolism Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Pulmonary Embolism Drug Market Size, 2022 & 2029
6.2 By Region – Global Pulmonary Embolism Drug Revenue & Forecasts
6.2.1 By Region – Global Pulmonary Embolism Drug Revenue, 2018-2023
6.2.2 By Region – Global Pulmonary Embolism Drug Revenue, 2024-2029
6.2.3 By Region – Global Pulmonary Embolism Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Pulmonary Embolism Drug Sales & Forecasts
6.3.1 By Region – Global Pulmonary Embolism Drug Sales, 2018-2023
6.3.2 By Region – Global Pulmonary Embolism Drug Sales, 2024-2029
6.3.3 By Region – Global Pulmonary Embolism Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Pulmonary Embolism Drug Revenue, 2018-2029
6.4.2 By Country – North America Pulmonary Embolism Drug Sales, 2018-2029
6.4.3 US Pulmonary Embolism Drug Market Size, 2018-2029
6.4.4 Canada Pulmonary Embolism Drug Market Size, 2018-2029
6.4.5 Mexico Pulmonary Embolism Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Pulmonary Embolism Drug Revenue, 2018-2029
6.5.2 By Country – Europe Pulmonary Embolism Drug Sales, 2018-2029
6.5.3 Germany Pulmonary Embolism Drug Market Size, 2018-2029
6.5.4 France Pulmonary Embolism Drug Market Size, 2018-2029
6.5.5 U.K. Pulmonary Embolism Drug Market Size, 2018-2029
6.5.6 Italy Pulmonary Embolism Drug Market Size, 2018-2029
6.5.7 Russia Pulmonary Embolism Drug Market Size, 2018-2029
6.5.8 Nordic Countries Pulmonary Embolism Drug Market Size, 2018-2029
6.5.9 Benelux Pulmonary Embolism Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Pulmonary Embolism Drug Revenue, 2018-2029
6.6.2 By Region – Asia Pulmonary Embolism Drug Sales, 2018-2029
6.6.3 China Pulmonary Embolism Drug Market Size, 2018-2029
6.6.4 Japan Pulmonary Embolism Drug Market Size, 2018-2029
6.6.5 South Korea Pulmonary Embolism Drug Market Size, 2018-2029
6.6.6 Southeast Asia Pulmonary Embolism Drug Market Size, 2018-2029
6.6.7 India Pulmonary Embolism Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Pulmonary Embolism Drug Revenue, 2018-2029
6.7.2 By Country – South America Pulmonary Embolism Drug Sales, 2018-2029
6.7.3 Brazil Pulmonary Embolism Drug Market Size, 2018-2029
6.7.4 Argentina Pulmonary Embolism Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Pulmonary Embolism Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Pulmonary Embolism Drug Sales, 2018-2029
6.8.3 Turkey Pulmonary Embolism Drug Market Size, 2018-2029
6.8.4 Israel Pulmonary Embolism Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Pulmonary Embolism Drug Market Size, 2018-2029
6.8.6 UAE Pulmonary Embolism Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Accu-Break Pharmaceuticals, Inc.
7.1.1 Accu-Break Pharmaceuticals, Inc. Company Summary
7.1.2 Accu-Break Pharmaceuticals, Inc. Business Overview
7.1.3 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Major Product Offerings
7.1.4 Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales and Revenue in Global (2018-2023)
7.1.5 Accu-Break Pharmaceuticals, Inc. Key News & Latest Developments
7.2 Dong-A Socio Holdings Co. Ltd.
7.2.1 Dong-A Socio Holdings Co. Ltd. Company Summary
7.2.2 Dong-A Socio Holdings Co. Ltd. Business Overview
7.2.3 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Major Product Offerings
7.2.4 Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales and Revenue in Global (2018-2023)
7.2.5 Dong-A Socio Holdings Co. Ltd. Key News & Latest Developments
7.3 F. Hoffmann-La Roche Ltd.
7.3.1 F. Hoffmann-La Roche Ltd. Company Summary
7.3.2 F. Hoffmann-La Roche Ltd. Business Overview
7.3.3 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Major Product Offerings
7.3.4 F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales and Revenue in Global (2018-2023)
7.3.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.4 Genentech, Inc.
7.4.1 Genentech, Inc. Company Summary
7.4.2 Genentech, Inc. Business Overview
7.4.3 Genentech, Inc. Pulmonary Embolism Drug Major Product Offerings
7.4.4 Genentech, Inc. Pulmonary Embolism Drug Sales and Revenue in Global (2018-2023)
7.4.5 Genentech, Inc. Key News & Latest Developments
7.5 Verseon Corp
7.5.1 Verseon Corp Company Summary
7.5.2 Verseon Corp Business Overview
7.5.3 Verseon Corp Pulmonary Embolism Drug Major Product Offerings
7.5.4 Verseon Corp Pulmonary Embolism Drug Sales and Revenue in Global (2018-2023)
7.5.5 Verseon Corp Key News & Latest Developments
8 Global Pulmonary Embolism Drug Production Capacity, Analysis
8.1 Global Pulmonary Embolism Drug Production Capacity, 2018-2029
8.2 Pulmonary Embolism Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Pulmonary Embolism Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Pulmonary Embolism Drug Supply Chain Analysis
10.1 Pulmonary Embolism Drug Industry Value Chain
10.2 Pulmonary Embolism Drug Upstream Market
10.3 Pulmonary Embolism Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Pulmonary Embolism Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Pulmonary Embolism Drug in Global Market
Table 2. Top Pulmonary Embolism Drug Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Pulmonary Embolism Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Pulmonary Embolism Drug Revenue Share by Companies, 2018-2023
Table 5. Global Pulmonary Embolism Drug Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Pulmonary Embolism Drug Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Pulmonary Embolism Drug Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Pulmonary Embolism Drug Product Type
Table 9. List of Global Tier 1 Pulmonary Embolism Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Pulmonary Embolism Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Pulmonary Embolism Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Pulmonary Embolism Drug Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Pulmonary Embolism Drug Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Pulmonary Embolism Drug Sales (K Pcs), 2018-2023
Table 15. By Type - Global Pulmonary Embolism Drug Sales (K Pcs), 2024-2029
Table 16. By Application – Global Pulmonary Embolism Drug Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Pulmonary Embolism Drug Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Pulmonary Embolism Drug Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Pulmonary Embolism Drug Sales (K Pcs), 2018-2023
Table 20. By Application - Global Pulmonary Embolism Drug Sales (K Pcs), 2024-2029
Table 21. By Region – Global Pulmonary Embolism Drug Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Pulmonary Embolism Drug Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Pulmonary Embolism Drug Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Pulmonary Embolism Drug Sales (K Pcs), 2018-2023
Table 25. By Region - Global Pulmonary Embolism Drug Sales (K Pcs), 2024-2029
Table 26. By Country - North America Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Pulmonary Embolism Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Pulmonary Embolism Drug Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Pulmonary Embolism Drug Sales, (K Pcs), 2024-2029
Table 30. By Country - Europe Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Pulmonary Embolism Drug Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Pulmonary Embolism Drug Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Pulmonary Embolism Drug Sales, (K Pcs), 2024-2029
Table 34. By Region - Asia Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Pulmonary Embolism Drug Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Pulmonary Embolism Drug Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Pulmonary Embolism Drug Sales, (K Pcs), 2024-2029
Table 38. By Country - South America Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Pulmonary Embolism Drug Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Pulmonary Embolism Drug Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Pulmonary Embolism Drug Sales, (K Pcs), 2024-2029
Table 42. By Country - Middle East & Africa Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Pulmonary Embolism Drug Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Pulmonary Embolism Drug Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Pulmonary Embolism Drug Sales, (K Pcs), 2024-2029
Table 46. Accu-Break Pharmaceuticals, Inc. Company Summary
Table 47. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Product Offerings
Table 48. Accu-Break Pharmaceuticals, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Accu-Break Pharmaceuticals, Inc. Key News & Latest Developments
Table 50. Dong-A Socio Holdings Co. Ltd. Company Summary
Table 51. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Product Offerings
Table 52. Dong-A Socio Holdings Co. Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Dong-A Socio Holdings Co. Ltd. Key News & Latest Developments
Table 54. F. Hoffmann-La Roche Ltd. Company Summary
Table 55. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Product Offerings
Table 56. F. Hoffmann-La Roche Ltd. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 58. Genentech, Inc. Company Summary
Table 59. Genentech, Inc. Pulmonary Embolism Drug Product Offerings
Table 60. Genentech, Inc. Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Genentech, Inc. Key News & Latest Developments
Table 62. Verseon Corp Company Summary
Table 63. Verseon Corp Pulmonary Embolism Drug Product Offerings
Table 64. Verseon Corp Pulmonary Embolism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Verseon Corp Key News & Latest Developments
Table 66. Pulmonary Embolism Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 67. Global Pulmonary Embolism Drug Capacity Market Share of Key Manufacturers, 2021-2023
Table 68. Global Pulmonary Embolism Drug Production by Region, 2018-2023 (K Pcs)
Table 69. Global Pulmonary Embolism Drug Production by Region, 2024-2029 (K Pcs)
Table 70. Pulmonary Embolism Drug Market Opportunities & Trends in Global Market
Table 71. Pulmonary Embolism Drug Market Drivers in Global Market
Table 72. Pulmonary Embolism Drug Market Restraints in Global Market
Table 73. Pulmonary Embolism Drug Raw Materials
Table 74. Pulmonary Embolism Drug Raw Materials Suppliers in Global Market
Table 75. Typical Pulmonary Embolism Drug Downstream
Table 76. Pulmonary Embolism Drug Downstream Clients in Global Market
Table 77. Pulmonary Embolism Drug Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Pulmonary Embolism Drug Segment by Type in 2022
Figure 2. Pulmonary Embolism Drug Segment by Application in 2022
Figure 3. Global Pulmonary Embolism Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Pulmonary Embolism Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Pulmonary Embolism Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. Pulmonary Embolism Drug Sales in Global Market: 2018-2029 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Pulmonary Embolism Drug Revenue in 2022
Figure 9. By Type - Global Pulmonary Embolism Drug Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Pulmonary Embolism Drug Revenue Market Share, 2018-2029
Figure 11. By Type - Global Pulmonary Embolism Drug Sales Market Share, 2018-2029
Figure 12. By Type - Global Pulmonary Embolism Drug Price (USD/Pcs), 2018-2029
Figure 13. By Application - Global Pulmonary Embolism Drug Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Pulmonary Embolism Drug Revenue Market Share, 2018-2029
Figure 15. By Application - Global Pulmonary Embolism Drug Sales Market Share, 2018-2029
Figure 16. By Application - Global Pulmonary Embolism Drug Price (USD/Pcs), 2018-2029
Figure 17. By Region - Global Pulmonary Embolism Drug Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Pulmonary Embolism Drug Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Pulmonary Embolism Drug Revenue Market Share, 2018-2029
Figure 20. By Region - Global Pulmonary Embolism Drug Sales Market Share, 2018-2029
Figure 21. By Country - North America Pulmonary Embolism Drug Revenue Market Share, 2018-2029
Figure 22. By Country - North America Pulmonary Embolism Drug Sales Market Share, 2018-2029
Figure 23. US Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Pulmonary Embolism Drug Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Pulmonary Embolism Drug Sales Market Share, 2018-2029
Figure 28. Germany Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 29. France Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Pulmonary Embolism Drug Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Pulmonary Embolism Drug Sales Market Share, 2018-2029
Figure 37. China Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 41. India Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Pulmonary Embolism Drug Revenue Market Share, 2018-2029
Figure 43. By Country - South America Pulmonary Embolism Drug Sales Market Share, 2018-2029
Figure 44. Brazil Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Pulmonary Embolism Drug Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Pulmonary Embolism Drug Sales Market Share, 2018-2029
Figure 48. Turkey Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Pulmonary Embolism Drug Revenue, (US$, Mn), 2018-2029
Figure 52. Global Pulmonary Embolism Drug Production Capacity (K Pcs), 2018-2029
Figure 53. The Percentage of Production Pulmonary Embolism Drug by Region, 2022 VS 2029
Figure 54. Pulmonary Embolism Drug Industry Value Chain
Figure 55. Marketing Channels


★調査レポート[世界の肺塞栓症治療薬市場予測2023-2029：DS-9231、DS-1040、TRX-1、その他] (コード：MMG23LY8619)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の肺塞栓症治療薬市場予測2023-2029：DS-9231、DS-1040、TRX-1、その他]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の肺動脈高血圧症治療市場予測2023-2029：血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬
  • 世界のソリリス薬市場予測2023-2029：血漿交換、血漿注入
  • 世界のレナリドマイド薬市場予測2023-2029：5mgカプセル、10mgカプセル、15mgカプセル、25mgカプセル
  • 世界の心臓用薬剤コーティングバルーン市場予測2023-2029：パクリタキセルコーティング型、その他コーティング型
  • 世界のピモジド抗精神病薬市場予測2023-2029：1Mg、2Mg、4Mg

    • ◆H&Iグローバルリサーチのお客様（例）◆